🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

⏰ #ASH22 LATE BREAKING ABSTRACT ANNOUNCEMENT! ⏰ It's a big year for post-transplant cyclophosphamide (PTCy) and BMT CTN! The primary analysis of #BMTCTN1703 is here! ash.confex.com/ash/2022/webpr… A thread 🧵/ ASH Clinical News ASH

Now OF and OA: A multicentre, observational cohort study suggests that a sex-informed approach can improve the personalised decision making process in patients with myelodysplastic syndromes. #mdssm thelancet.com/journals/lanha…

"These findings strongly support the integration of sex into the clinical risk assessment of myelodysplastic syndromes, albeit with only a modest hazard effect that appears specific to lower-risk disease phenotypes." Comment by Michael Hochman and Amy DeZern thelancet.com/journals/lanha…

Hanging out at Ashapalooza with Leuk and a spectacular hematologist - Mike Hochman. #Ash22

Hahaha. Omg, I love it! When your Division Director and soon-to-be ASH President nails the heme puns, you know you went into the right specialty. ❤️🩸#HemeRules #BloodyBrilliant ASH Johns Hopkins Hematology

The most important trial at #ASH22: NEUTRODIET, a randomized multicenter trial of 'neutropenic diet' vs normal diet after auto/alloSCT. No differences in infections, aGHVD or hospital days between arms. Less weight loss & better patient satisfaction in normal diet arm! #tcellrx

Part of the Johns Hopkins malig heme cohort at #ASH2022 B Douglas Smith

It is clear. If there is one thing we owe to patients, hemato-oncologists, pathologists, clinical trialists, scientists & regulators is to unify the CAC/ICC & WHO classification ASAP. Why wait for the next revision? #ASH22 inspiration

⁦Chris Hourigan⁩ presenting words of wisdom from our great mentor Judy Karp at the #ASH22 AML education session.

Hematology: always leading the way with the least pronounceable new drug names in medicine. #ASH22

Congratulations to Johns Hopkins Hematology Division Director Dr. Robert Brodsky as he takes on his new role as ASH President 2023! With his inspiring leadership, hematology is in great hands. We can’t wait to see what this next year will bring!! 🩸🌟 #HemeDreamTeam Robert Brodsky

How I prevent #GVHD in high-risk patients: posttransplant cyclophosphamide and beyond loom.ly/5wCEJlI

Hematology workforce shortage? How we got here and how we are addessing it. #ASHTrainee#classicalheme#HFFTP ashpublications.org/thehematologis…

We are thrilled, excited, and proud to announce our chiefs for AY24. Dr. @saumarai, Dr. Govind Warrier MD, MPH, and Dr. Catherine Wilbur. #1Fellowship1Family. Looking forward to the great things you will accomplish in your roles.

📰Our new contribution using the National MDS Study Cohort. Led by the amazing Amy DeZern Mikkael A. Sekeres MD, MS and many many others. #MDSsm Utility of Targeted Gene Sequencing to Differentiate Myeloid Malignancies from other Cytopenic Conditions ashpublications.org/bloodadvances/…

Congratulations to Michael Hochman and co-authors: nature.com/articles/s4137…

Excited to share my review of higher-risk MDS, published in Clinical Lymphoma, Myeloma and Leukemia and written with the amazing Amy DeZern!: authors.elsevier.com/c/1iud37fNb0Dz…… "Hopefully the MDS community now sits at a turning point in history for HR-MDS." Elsevier

Managing Myeloid Neoplasms With Low-Risk Phenotype and High-Risk Mutations Is a New Frontier dailynews.ascopubs.org/do/managing-my…